Deals channel feed – Endpoints News

Deals channel feed

Third antigen's a charm: Gilead pens deal with Merus for up to three trispecific antibodies

Last year

Australian biopharma buys radioisotope producer in its next step to ‘double’ capacity in 2024

Last year

Sandoz completes $170M buy of Lucentis biosimilar from Coherus BioSciences

Last year

Corrected: Merck KGaA bags another protein degrader deal for $16M upfront, this time with C4

Last year

Bayer buys European rights to BridgeBio's ATTR-CM pill

Last year

Societal CDMO to be bought by another manufacturer, CoreRx, for $1.10 a share

Last year

AbbVie bets $48M upfront for early-stage antibody targeting chronic inflammation

Last year

Viatris licenses Idorsia’s PhIII heart and lupus drugs with $350M upfront

Last year

AstraZeneca bails on roxadustat’s future in the US, but keeps China pact with FibroGen

Last year

Novo Nordisk inks pact for discovery of 'molecular glues' in deal worth as much as $1.46B

Last year

NGM Bio to revert to private company as MASH potential remains unclear

Last year

BeiGene ends pact with Shoreline, its 'entry into cell therapy'

Last year

Gilead bid against itself in $4.3B deal for CymaBay, filing shows

Last year

Like Gilead, AbbVie gets its tentacles into pact with Tentarix

Last year

Novavax and Gavi settle over Covid-19 vaccine partnership dispute

Last year

Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia Therapeutics

Last year

Novo-Catalent deal likely to be one-off — with some caveats, insiders say

Last year

Roche walks away from Repare solid tumor deal just weeks after $40M milestone payout

Last year

Gilead's newest acquisition: a liver disease drug with $1B in peak sales potential

Last year

FTC review periods end for AbbVie-ImmunoGen $10.1B deal and $4B BMS-RayzeBio buyout

Last year

Gilead to snap up liver disease biotech CymaBay for $4.3B

Last year

BioNTech, Autolus strike wide-ranging licensing and manufacturing deal for CAR-T therapies

Last year

Lilly CEO raises concerns about Novo-Catalent buy, calling the Novo Nordisk deal ‘unusual’

Last year

After sweep of deals in 2023, Gilead to focus on 'late research, early development' pipeline

Last year

First page Previous page 18 19 202122 23 24 Next page Last page